Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Other Non-Current Liabilities (2017 - 2025)

Cytokinetics (CYTK) has disclosed Other Non-Current Liabilities for 10 consecutive years, with $27.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Liabilities changed N/A to $27.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $27.9 million, a N/A change, with the full-year FY2025 number at $27.9 million, changed N/A from a year prior.
  • Other Non-Current Liabilities was $27.9 million for Q4 2025 at Cytokinetics, up from $1.6 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $174.8 million in Q3 2021 to a low of $408000.0 in Q3 2023.
  • A 5-year average of $39.6 million and a median of $8.1 million in 2021 define the central range for Other Non-Current Liabilities.
  • Peak YoY movement for Other Non-Current Liabilities: crashed 99.29% in 2022, then skyrocketed 16652.0% in 2024.
  • Cytokinetics' Other Non-Current Liabilities stood at $4.5 million in 2021, then plummeted by 76.58% to $1.0 million in 2022, then surged by 1106.9% to $12.6 million in 2023, then surged by 730.95% to $104.7 million in 2024, then crashed by 73.35% to $27.9 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Other Non-Current Liabilities are $27.9 million (Q4 2025), $1.6 million (Q3 2025), and $12.8 million (Q2 2025).